Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: tomorrow

Maybe the big name(s) is saved for the day the Q is issued; might help to support a big run.

The good news is that the company cannot begin to re-start share repurchases until it reports the Q; which implicity means they will have to share ALL of what has transpired and is ongoing. In other words, I don't think there can be any subterfuge or vagaries associated with the Q; all the cards need to be showing.

That is not to say the Q is going to meet or exceed everyone's highest expectations, because revenue recognition treatments adopted may allow for revenue to be recognized over extended periods depending on the structure of the settlement agreements.

Best

Share
New Message
Please login to post a reply